Blending both genetic test status AND personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing. Myriad myRisk identifies elevated risk for 8 important cancers by analyzing multiple, clinically significant genes. In addition, myRisk’s assessment of the BRCA1 and BRCA2 genes can help inform treatment decisions related to PARP inhibitor therapy.1-4
Inform Treatment Decisions
- Cancer cells with BRCA1 or BRCA2 mutations are more susceptible to PARP inhibitors and treatments that directly or indirectly damage DNA (DNA damaging agents).1-4
- Knowing BRCA1 and BRCA2 status may inform treatment decisions related to PARP inhibitors and DNA damaging agents
How does testing impact treatment decisions related to PARP inhibitors and DNA damaging agents?
Manage Future Cancer Risk
- Myriad myRisk simplifies the test selection process by providing you the most comprehensive hereditary cancer panel test with clinically significant results. Be confident you are testing for the primary clinically significant genes associated with your patients’ risk.
- First-degree relatives of these patients are at a 50% risk for carrying the mutation.
- Those relatives who are positive may benefit from increased surveillance and/or preventive measures.
What are the future cancer risks for your patients and their families?
In the SOLO2 trial, a significant improvement in progression-free survival in patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer when treated with the PARP inhibitor olaparib. Other studies such as Study 19, ARIEL2 and NOVA demonstrated that a germline BRCA1/2 mutation can be a predictor of increased efficacy with PARP inhibitor therapy.
Explore our publications to learn more about how BRCA1/2 testing can impact treatment decisions related to PARP inhibitor therapy and DNA-damaging chemotherapy in ovarian cancer.
Myriad is the unquestioned industry leader in variant classification and reclassification. myVision® is the most advanced program in the industry overseeing the classification and reclassification of uncertain variants and is part of Myriad’s commitment to patients and their families that lasts a lifetime.
MYRIAD HAS CONDUCTED OVER
TESTS FOR HEREDITARY CANCER
* BRACAnalysis CDx has been approved by the FDA for patients with breast and ovarian cancer who are or may become eligible for treatment with the PARP inhibitor Lynparza® (olaparib). BRACAnalysis CDx can also identify patients with ovarian cancer who may experience enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. myRisk, myChoice HRD and BRACAnalysis have not been reviewed or approved by the FDA.1,2
- Ledermann et al. Lancet Oncol. (2014). 15:852-61.
- Kristeleit et al. Presented at European Cancer Congress 2016 (Abstract 8560).
- Lheureux et al. J Clin Oncol (2015). 33 (suppl;abstr 5566).
- Pujade-Lauraine et al. Lancet Oncol (2017). ttp://dx.doi.org/10.1016/S1470-2045(17)30469-2